<DOC>
	<DOCNO>NCT00102011</DOCNO>
	<brief_summary>RATIONALE : Screening test , colonoscopy fecal occult blood test , may help doctor find tumor cell early plan well treatment colorectal cancer . PURPOSE : This randomized phase III trial study colonoscopy see well work compare fecal occult blood test screen healthy participant colorectal cancer .</brief_summary>
	<brief_title>Colonoscopy Fecal Occult Blood Test Screening Healthy Participants Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare neoplastic outcome participant average risk colorectal cancer undergo colonoscopy vs annual fecal occult blood test . - Compare endoscopic clinical resource require screen method participant . - Compare benefit-to-harm ratio participant undergo screen method . - Determine level participation participant undergo screen method . OUTLINE : This randomize , two-part , multicenter study . Participants ask whether interested participate randomize controlled trial colorectal cancer screen . - Screening colonoscopy feasibility study I ( accrual complete 12/14/2004 ) : Participants interested participate screen trial randomize 1 2 screening arm . - Arm I : Participants undergo baseline screening colonoscopy . - Arm II : Participants receive standard care . - Screening colonoscopy feasibility study II : Participants interested participate screen trial randomize 1 2 screening arm . - Arm I : Participants undergo baseline screening colonoscopy . Participants give individualized recommendation surveillance base result colonoscopy . - Arm II : Participants undergo baseline fecal occult blood test ( FOBT ) . Participants give individualized recommendation surveillance base result FOBT . Participants negative baseline FOBT undergo FOBT annually 4 year absence positive FOBT . All participant follow annually 4 year . PROJECTED ACCRUAL : A total 1,402 participant ( 701 per screen arm ) accrue feasibility study I within 3 year ( accrual complete 12/14/2004 ) . An additional 3,550 participant ( 1,775 per screen arm ) accrue feasibility study II within 5 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Healthy participant average risk develop colorectal cancer No history colorectal cancer No history familial adenomatous polyposis More 5 year since prior flexible sigmoidoscopy No prior colonoscopy PATIENT CHARACTERISTICS : Age 50 69 ( 40 69 Louisiana State University participate site ) Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Cardiovascular No myocardial infarction within past year No congestive heart failure Pulmonary No chronic obstructive pulmonary disease Gastrointestinal No history ulcerative colitis No history Crohn 's disease No history inflammatory bowel disease Other No serious comorbid condition No consumption red meat within 3 day prior FOBT ( feasibility study II , arm II ) PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No concurrent chemotherapy nonmelanoma skin cancer Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other No vitamin C consumption &gt; 250 mg within 3 day prior fecal occult blood testing ( FOBT ) ( feasibility study II arm II ) No nonsteroidal antiinflammatory drug within 7 day prior FOBT ( feasibility study II , arm II ) No concurrent anticoagulants No concurrent anticancer therapy except treatment nonmelanoma skin cancer</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>colon cancer</keyword>
	<keyword>rectal cancer</keyword>
</DOC>